I am a consultant urologist and robotic surgeon, and I begin consulting at SJMC on 4 January 2027, having served as faculty and attending (consultant) urological cancer surgeon at Yale University following advanced clinical and research training at University College London Hospitals (UCLH) and MD Anderson Cancer Center — ranked among the world’s top urology and cancer hospitals respectively in Newsweek’s World’s Best Specialized Hospitals 2027. I was also awarded the Hunterian Professorship by the Royal College of Surgeons of England in 2026 for my contributions to surgical advancement.
Prior to returning to Malaysia, I served as an attending (consultant) urological cancer surgeon at Yale University and the Yale Cancer Center. I currently hold an Adjunct Professorship from Yale University and an Honorary Associate Professorship from UCL.
Where it is oncologically safe, I use function-preserving techniques including nerve-sparing and Retzius-sparing prostatectomy, and organ-sparing robotic cystectomy with intracorporeal urinary diversion.
My aim is to provide evidence-based cancer care to patients in Malaysia, delivered with attention to each individual’s circumstances and priorities.
I completed my medical training at Cardiff University in 2010 and went on to earn a PhD in Uro-oncology at University College London (UCL). I was selected for the National Institute for Health Research (NIHR) Academic Clinical Fellow (ACF) in Urology residency programme at UCL, a highly selective programme that trains future academic leaders in urology. My urology residency was completed at the London School of Surgery, rotating through UCLH, the Royal Free Hospital, and Imperial College Healthcare, culminating in the Fellowship of the Royal College of Surgeons in Urology (FRCS Urol).
I then completed a Robotic Urology fellowship at UCLH followed by a Society of Urologic Oncology (SUO) Fellowship at MD Anderson Cancer Center.
A cancer diagnosis is one of the most frightening things a person can face. My role is not only to treat your cancer — it is to make sure you feel supported, informed, and genuinely cared for at every step of the journey.
I take time to understand your situation fully before recommending anything. You will always receive a clear explanation of your diagnosis, your options, and what to expect — in language that makes sense to you. No decision is made without your understanding and agreement.
Where appropriate, this includes discussing surveillance as well as treatment, so that we can decide together. Complex cancer cases are also discussed with colleagues in a multidisciplinary team.
My aim is to provide high-quality care — here, in Malaysia.